A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia Clinical Trial

— IbruOnOff  

Official title:

A Pilot Study on Intermittent and Repeated Dosing of Ibrutinib in the Treatment of Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04771507
• Other study ID #: HCK-LT-CLL02/2017
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 23, 2018
• Est. completion date: December 1, 2027

Study information

• Verified date: February 2021
• Source: Karolinska University Hospital
• Contact: Jeanette Lundin, MD PhD
• Phone: 0700 85 67 86
• Email: jeanette.lundin[@]sll.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ibrutinib, an inhibitor of Bruton´s tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care are rapidly increasing and are difficult to predict, as long-term follow up analyses have shown that many patients remain on therapy for several years, in some cases even many years. It has been observed that patients who stop ibrutinib due to side effects may often remain with continued CLL disease control i.e. in stable partial remission even when off ibrutinib therapy. There are also emerging data on mutations within BTK, with loss of efficacy of ibrutinib, during long-term continuous administration. These observations raise the question whether alternative dosing strategies may be feasible. This pilot study will explore intermittent and repeated dosing of ibrutinib, until alternative therapy is required due to resistance or intolerance to ibrutinib. An "ON-OFF" dosing strategy will be applied, where advanced-phase CLL patients who have received at least 6 months of ibrutinib and who have achieved a stable PR will stop ibrutinib and be followed off therapy until clinical progression, at which ibrutinib will be re-instituted. Such "ON-OFF" ibrutinib cycles may be repeated until non-tolerability or resistance, or need of continuous dosing of ibrutinib (i.e. early progression when off the drug). If successful, the study will indicate a way forward towards reducing ibrutinib drug costs in health care without affecting long-term disease control, possibly also with fewer ibrutinib-related side effects due to a lower cumulative dose of ibrutinib. Long-term effects on potential mutations within BTK and its downstream signaling molecules will also be analysed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 1, 2027
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and voluntarily provide written informed consent and comply with the requirements of the study.

2. Age 18 years and older. There is no upper age limit in this trial.

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Before start ibrutinib for the first time: diagnosed with CLL/SLL and active disease in need of treatment after having failed chemoimmunotherapy for CLL defined as a) refractory according to iwCLL criteria; or b) relapsed and deemed not suitable for additional chemo- or chemoimmunotherapy or c) del 17p and/or TP53 mutation irrespective of prior therapy.

5. Having received at least 6 months of ibrutinib therapy and having achieved at least clinical PR according to IWCLL criteria.

6. ECOG performance status of </= 2 at screening.

7. Laboratory test results:

• Absolute neutrophil count >/= 0.5 x 109/L

• Platelet count >/= 30 x 109/L

• Serum creatinine < 177 µmol/L

• ASAT (SGOT) and ALAT (SGPT) >/= 2 x ULN or >/= 5 x ULN unless attributable to CLL/SLL

8. Disease free of prior malignancies for >/= 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.

9. Agree to use reliable forms of contraception. Post-menopausal females and surgically sterilized females are exempt from this criterion.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

2. Pregnant or breast feeding females.

3. Any condition, including the presence of laboratory abnormalities, which according to the responsible physician places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

4. Use of any other experimental therapy within the last 14 days.

5. Concurrent use of other anti-cancer agents or treatments than ibrutinib (except a low dose of corticosteroids, max 10 mg of prednisone/day).

6. Positivity for HIV or infectious hepatitis, type A, B or C.

7. Opportunistic infections within the last 3 months.

8. Patient planned for or being a potential candidate for allo-SCT.

9. Uncontrolled hemolytic anemia or autoimmune thrombocytopenia.

10. CNS involvement or history of Richter's transformation.

11. Requires or has received anticoagulation treatment with warfarin or equivalent Vitamin K antagonists (eg, phenprocoumon) within 28 days of the first dose of ibrutinib.

12. Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor.

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Small Lymphocytic Lymphoma

Intervention

Drug:
• Ibrutinib
Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.

Locations

Country	Name	City	State
Norway	St Olavs Hospital	Trondheim
Sweden	Falu lasarett	Falun	Dalarna
Sweden	Gävle Hospital	Gävle	Gävleborg
Sweden	Sahlgrenska University Hospital	Gothenburg
Sweden	Skåne University Hospital	Lund	Skåne
Sweden	Örebro University Hospital	Örebro
Sweden	Karolinska University Hospital	Stockholm
Sweden	Norrland's University Hospital	Umeå
Sweden	Akademiska hospital	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Jeanette Lundin

Countries where clinical trial is conducted

Norway,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety measured as type, frequency and severity of adverse events.	Type, frequency and severity of adverse events and relationship to intermittent ibrutinib dosing.	Through study completion, 1-24 months.
Secondary	Overall response at each treatment cycle.	Response when re-starting ibrutinib, at each cycle.	Through study completion, 1-24 months.
Secondary	Time to PR and PR-L at each cycle.	Time to partial response (PR) and partial response with persistent lymphocytosis (PR-L) when re-starting ibrutinib, at each cycle.	Through study completion, 1-24 months.
Secondary	Time to stop until restart of ibrutinib due to progress	Time from the patient going off ibrutinib until it has to be re-started due to progressive, for each cycle.disease (PD), at each cycle.	Through study completion, 1-24 months.
Secondary	Number of ibrutinib treatment cycles and OFF therapy periods.	The number of cycles each patient stop and re-start ibrutinib.	Through study completion, 1-24 months.
Secondary	Cumulative dose of ibrutinib.	The cumulative dose of ibrutinib for each patient.	Through study completion, 1-24 months.
Secondary	Overall survival.	Overall survival.	Through study completion, 1-24 months.
Secondary	Risk of early rebound phenomenon.	Observation of early rebound phenomemon at each re-start of ibrutinib.	Through study completion, 1-24 months.
Secondary	Time to need of alternative treatment.	Time to need of alternative treatment.	Through study completion, 1-24 months.